tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF) and Demant (OtherWILLF)

Analysts fell to the sidelines weighing in on Innate Pharma SA (IPHYFResearch Report) and Demant (WILLFResearch Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Innate Pharma SA (IPHYF)

Innate Pharma SA received a Hold rating and a EUR3.10 price target from Kepler Capital analyst Clémence Thiers on August 8. The company’s shares closed last Thursday at $2.78, close to its 52-week low of $2.27.

According to TipRanks.com, Thiers is ranked #5309 out of 8001 analysts.

Innate Pharma SA has an analyst consensus of Moderate Buy, with a price target consensus of $5.20.

See Insiders’ Hot Stocks on TipRanks >>

Demant (WILLF)

In a report issued on August 8, Maja Pataki from Kepler Capital maintained a Hold rating on Demant, with a price target of DKK290.00. The company’s shares closed last Thursday at $37.75, close to its 52-week low of $37.25.

According to TipRanks.com, Pataki is ranked #7895 out of 8001 analysts.

Currently, the analyst consensus on Demant is a Hold with an average price target of $41.77.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IPHYF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed